Navigation Links
DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants
Date:4/12/2017

VANCOUVER, British Columbia and MENLO PARK, Calif., April 12, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced a proposed registered public offering of its common stock and warrants to purchase common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as exclusive placement agent for the offering.

DelMar intends to use the net proceeds from the offering, if completed, for general corporate purposes, which may include working capital, capital expenditures, research and development and other commercial expenditures.

The shares and warrants are being offered pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-213601), that was previously filed with the Securities and Exchange Commission ("SEC") and declared effective on September 27, 2016. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov and may also be obtained from Rodman & Renshaw, a unit of H.C. Wainwright & Co., by calling (212) 856-5707 or emailing placements@hcwco.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About DelMar Pharmaceuticals, Inc.
DelMar was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. DelMar's VAL-083 is currently undergoing clinical trials in the U.S. as a potential new therapy for Glioblastoma Multiforme (GBM). VAL-083 has been extensively studied by the U.S. National Cancer Institutes, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on Twitter, LinkedIn, Facebook, and Google+. Investor Relations Counsel:  Amato & Partners LLC.

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-announces-proposed-public-offering-of-common-stock-and-warrants-300438971.html


'/>"/>
SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)
2. DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2016 Financial Results and Corporate Update
3. DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMars VAL-083 in Brain Cancer
4. DelMar Pharmaceuticals Updates VAL-083 Clinical Trial in Refractory Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting
5. DelMar Pharmaceuticals to Present at the 8th Annual LD Micro Main Event on December 2, 2015
6. DelMar Pharmaceuticals Presents Data Summarizing the Potential of VAL-083 as a New Treatment Option for Resistant Cancers
7. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors
8. DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC)
9. DelMar Pharmaceuticals to Present at the SeeThruEquity Microcap Investor Forum on November 12, 2015
10. DelMar Pharmaceuticals Announces the Completion of Enrollment in its Phase II Expansion Study of VAL-083 in Refractory Glioblastoma Multiforme
11. DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 as a Promising Treatment for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2019)... , ... June 15, 2019 , ... ... 1.4% of the global population. The condition is characterized by damage to ... complications including thyroid disease, anemia, osteoporosis, fertility problems and some cancers, to name ...
(Date:6/13/2019)... ... 13, 2019 , ... The Centers for Medicare & Medicaid ... Improvement and Innovation Contractor. This designation will allow NQIICs to bid on Task ... with other Quality Improvement contractors under the new CMS Indefinite Delivery/Indefinite Quantity (IDIQ) ...
(Date:6/13/2019)... ... June 13, 2019 , ... The American Psychiatric Nurses Association announced today ... executive director Nicholas Croce Jr., MS. The search will be led by an APNA ... APNA Presidents, and Council and Chapter leaders. , The job description and more information ...
Breaking Medicine Technology:
(Date:6/13/2019)... ... June 13, 2019 , ... MMJ BioPharma Cultivation, a ... a memorandum of understanding (MOU) with MMJ International Holdings to grow cannabis and ... MMJ BioPharma Cultivation will be supplying MMJIH with extracts from the marijuana plant ...
(Date:6/13/2019)... ... 2019 , ... Charm Sciences, Inc. is pleased to announce ... the 2019 National Conference of Interstate Milk Shipments for screening milk tankers according ... test was validated by third party laboratories working in collaboration with the AOAC ...
(Date:6/13/2019)... SAN DIEGO (PRWEB) , ... June 13, 2019 ... ... 96-hour pain relief patch, announces their partnership with cannabis delivery company, Driven Deliveries, ... , Driven Deliveries, Inc., covers 93% of the population of California with ...
(Date:6/13/2019)... Va. (PRWEB) , ... June 13, 2019 , ... ... awards programs, is proud to present the second annual Women|Future Conference ... that will allow attendees to better position themselves and their organizations in tomorrow's ...
(Date:6/13/2019)... , ... June 13, 2019 , ... ... to everyone in healthcare, today announced that Jon Elwell, the company’s CEO, has ... DirectTrust™. DirectTrust is a non-profit health care industry alliance created to ...
Breaking Medicine News(10 mins):